Study to Compare AMG 510 Proposed INN Sotorasib With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

Model scores of the 29,894 trials active now.

Model score 19% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 10% of the time (1,463 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2026-06-24. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: nsclcsubjects withbrainmyocardialinfarction
  Phrases that lowered it: labelopencomparestudy topreviously
• Sponsor's past termination rate: 11.2% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Maximum age: 100 (lowers risk) · Who can join
• Phase: 3 (lowers risk) · Design
• Drug's FAERS reports with a death: 10.8% (lowers risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 68 (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Design: parallel (raises risk) · Design
• Drug's FAERS reports marked serious: 77.4% (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports in the prior 12 months: 10567 (lowers risk) · Drug's FDA history
• Drug's FAERS reports before start: 60072 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients NCT00890825 · started 2009 · scored riskier than 52% of active trials completed
• Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer NCT01395758 · started 2011 · scored riskier than 80% of active trials completed
• A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer NCT05492045 · started 2022 · scored riskier than 50% of active trials terminated
• A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation NCT05756153 · started 2023 · scored riskier than 38% of active trials completed
• A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100) NCT03600883 · started 2018 · scored riskier than 78% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.